Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics

Bon San Koo1†, Seongho Eun2†, Kichul Shin3, Hyemin Yoon4, Chaelin Hong4, Do-Hoon Kim5, Seokchan Hong6, Yong-Gil Kim6, Chang-Keun Lee6, Bin Yoo6 and Ji Seon Oh5*

Abstract

Background: We developed a model to predict remissions in patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) and to identify important clinical features associated with remission using explainable artificial intelligence (XAI).

Methods: We gathered the follow-up data of 1204 patients treated with bDMARDs (etanercept, adalimumab, golimumab, infliximab, abatacept, and tocilizumab) from the Korean College of Rheumatology Biologics and Targeted Therapy Registry. Remission was predicted at 1-year follow-up using baseline clinical data obtained at the time of enrollment. Machine learning methods (e.g., lasso, ridge, support vector machine, random forest, and XGBoost) were used for the predictions. The Shapley additive explanation (SHAP) value was used for interpretability of the predictions.

Results: The ranges for accuracy and area under the receiver operating characteristic of the newly developed machine learning model for predicting remission were 52.8–72.9% and 0.511–0.694, respectively. The Shapley plot in XAI showed that the impacts of the variables on predicting remission differed for each bDMARD. The most important features were age for adalimumab, rheumatoid factor for etanercept, erythrocyte sedimentation rate for infliximab and golimumab, disease duration for abatacept, and C-reactive protein for tocilizumab, with mean SHAP values of −0.250, −0.234, −0.514, −0.227, −0.804, and 0.135, respectively.

Conclusions: Our proposed machine learning model successfully identified clinical features that were predictive of remission in each of the bDMARDs. This approach may be useful for improving treatment outcomes by identifying clinical information related to remissions in patients with rheumatoid arthritis.

Keywords: Rheumatoid arthritis, Biologics, Remission, Machine learning, Explainable artificial intelligence

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the synovial tissues in multiple joints. Biologics are often considered a promising line of treatment for patients who have high disease activities despite treatment with conventional disease-modifying anti-rheumatic drugs (cDMARDs) [1–3]. Biologics are
generally prescribed by referring to clinical practice recommendations after considering factors such as disease activity, adverse events, and cost effectiveness [1–3]. However, treatment with biologics may be unsuccessful because of differences in the physiological and pathological characteristics among individuals. Indeed, clinical trials have frequently shown that approximately 30–40% of patients do not respond to treatment with biologics, and their response rates decrease with subsequent biologics [4, 5]. Treatment failure due to ineffective biologics not only increases the pain experienced by the individual but also increases their cost of healthcare [6]. Therefore, it is necessary to develop good predictors that can identify the efficacies of different biologics for such individuals.

Several clinical, genetic, and proteomic studies have used statistical methods to identify biomarkers to predict responses to biologics in patients with RA [7–9]. Machine learning approaches that can complement statistical methods are able to incorporate such information for making accurate predictions. Furthermore, machine learning can be generalized across a broader array of data types and can produce results with complex situations as well [10, 11]. However, it is often difficult for users to understand the processes by which machine learning predicts outcomes from relationships among numerous variables. Accordingly, several methods have been proposed to improve the interpretability of machine learning methods while maintaining the prediction accuracies of complex models. Explainable artificial intelligence (XAI), which presents the reasons for a prediction in a manner that can be understood, suggests the relationships between several variables necessary for predicting outcomes [12].

In the field of artificial intelligence, XAI was recently developed to help our understanding of the important features that are related to predicting the outcomes of machine learning models. In the study of RA with various clinical characteristics, it is possible to use the machine learning method to predict outcomes such as remission and show important clinical features that are associated with the desired outcomes. Therefore, predicting remission with a machine learning model by combining multiple variables in RA cohort data and identifying important features associated with remission by using XAI is an advanced approach that complements the traditional statistical methods for determining the relationship between remission and various variables.

In this study, we established a machine learning model using data from the Korean College of Rheumatology Biologics and Targeted Therapy Registry (KOBIO) [13] and show its application to identifying clinical variables predictive of remission in RA patients treated with biologics using the concept of XAI.
Five machine learning models were used to predict remission in subjects receiving bDMARDs, tumor necrosis factor (TNF) inhibitors, non-TNF inhibitors, and each bDMARD; the models included lasso and ridge based on linear relationships [14], support vector machine using kernel methods [15], tree-based random forest [16], and Xgboost [17]. To avoid overfitting problems, the training and test sets were divided in a 7:3 ratio, and the models were trained with the training set; then, the prediction results were verified using the test set. For the training dataset, a 5-fold cross validation was performed to tune the hyperparameters determined as outside models (Additional file: Table S1 and Table S2). In this procedure, a grid search was conducted to evaluate all possible combinations of the hyperparameters. The grid search found optimal hyperparameters with the objective function of determining the area under the receiver operating characteristics (AUROC) in each model. Bootstrapping (random sampling with replacement) was also performed to obtain a median value for the AUROC curve and to determine the accuracy for reducing measurement variances caused by small samples when dividing between the training and test sets.

Dimension reduction was performed to avoid the “curse of dimensionality” caused by a large number of variables compared with the size of the data. Among the 64 variables, we selected variables that are frequently encountered in clinical practice for prescription of biologics and excluded variables that are not referenced when prescribing biologics. As a result, 15 variables known to be of clinical importance were preselected (i.e., sex, age, baseline DAS28-ESR, methotrexate dose, steroid dose, erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], rheumatoid factor [RF], anticyclic citrullinated peptide antibody [ACPA], antinuclear antibody [ANA], and five comorbidities). Subsequently, 20 variables that were highly correlated with the drug response (remission) of each bDMARD were selected. After selecting variables based on data, we created a prediction model by training with a fixed set of 35 variables.
Missing data for variables (Additional file: Table S3) were replaced with the median value for each variable. With a similar logic, binary variables such as comorbidities were coded as 1 if “yes” and 0 if “no” or “no test” because “no” was the most common value.

**XAI for identifying important clinical features associated with responses to bDMARDs**

Using the Xgboost machine learning model, the important variables and their impact on predicting remissions using XAI were determined. By focusing on improving the performance and accuracy, machine learning models have become complex, and their interpretability has declined. Although there are some feature importance measures in random forest and Xgboost, these models provide inconsistent results depending on the tree structure; in addition, they only show the overall importance and not the direction of the effect of the independent variables [12]. To overcome these issues, the Shapley additive explanations (SHAP) method was developed [18], which approximates a complex model to a linear model and interprets the feature importance in the linear model to demonstrate the amount by which a given feature changes the prediction. In addition, XAI provides a Shapley plot that can be easily explained visually and easily to understand the complex relationship between variables and outcomes compared to random forest. This methodology satisfies three conditions: (1) the approximated linear model has a similar accuracy to the original model in the local domain, (2) meaningless variables have no impact on the explanatory power of the model, and (3) feature importance is consistent in the model structure. Accordingly, the SHAP method demonstrates consistent feature importance regardless of model structure and direction of effect of the predictive variables, thereby allowing clinicians to acquire insights into achieving remission and to find potential variables affecting the selection of appropriate bDMARDs.

**Statistical analysis**

All data are shown as mean (standard deviation [SD]) or percentage values. To evaluate the machine learning performance, the accuracy and AUROC curve were analyzed. The no information rate, which is the largest proportion of the observed classes, was used as a baseline to determine the overall distribution of the classification and to compare with those of the machine learning models. Statistical analyses were performed using R software version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria), and model training was performed using the caret package and SHAPforxgboost package in R.

**Results**

**Clinical characteristics of the patients**

Table 1 shows the clinical characteristics of the 1204 patients included in the study. The mean (SD) age at baseline was 54.0 (12.8) years and the majority (82.6%) of the patients were female. The mean (SD) disease duration was 7.1 (7.2) years. The rheumatoid factor (RF) and ACPA positivity were 83.2% and 73.4%, respectively, and the mean (SD) DAS28-ESR values at baseline and follow-up were 5.6 (1.0) and 4.3 (1.3), respectively. The mean (SD) duration from the initiation of biologics to the next visit was 0.97 (0.31) years. Of the 1397 follow-up data, 546 reached remission that is not more than 2.6 of DAS28-ESR; in those follow-up data, the mean (SD) number of follow-up visits and the duration of follow-up

| Variable                        | Value         |
|---------------------------------|---------------|
| Age, mean (SD), year            | 54.0 (12.8)   |
| Female (%)                      | 82.6          |
| Disease duration, mean (SD), year| 7.1 (7.2)     |
| Non-smoking (%)                 | 84.4          |
| History of cardiovascular diseases (%) | 3.9          |
| History of lung diseases (%)    | 6.1           |
| History of hematological diseases (%) | 1.3           |
| HBsAg positivity (%)            | 3.5           |
| HBsAb positivity (%)            | 46.7          |
| HBCAb positivity (%)            | 7.6           |
| HCV Ab positivity (%)           | 0.75          |
| Rheumatoid factor positivity (%)| 83.2          |
| Rheumatoid factor, mean (SD), mg/dL | 141.6 (216.8) |
| Anti-CCP antibody positivity (%)| 73.4          |
| Anti-CCP antibody, mean (SD), mg/dL | 190.3 (242.1) |
| Erythrocyte sedimentation rate, mean (SD), mm/h | 48.6 (26.8) |
| C-reactive protein, mean (SD), mg/dL | 2.4 (3.0) |
| Anti-nuclear antibody (%)       | 35.4          |
| Methotrexate treatment (%)      | 83.7          |
| Methotrexate dose, mean (SD), mg | 10.5 (5.4)   |
| Treatment of cDMARDs other than methotrexate (%) | 33.6 |
| Predisolone treatment (%)       | 71.1          |
| Predisolone dose, mean (SD), mg | 5.0 (3.8)    |

| DAS28-ESR at baseline, mean (SD) | 5.6 (1.0) |
| DAS28-ESR at follow-up, mean (SD) (N = 1397) | 4.3 (1.3) |

*Including leflunomide, sulfasalazine, hydroxychloroquine, or tacrolimus

*Corticosteroid dose (e.g., prednisolone, methylprednisolone, deflazacort, and dexamethasone) was converted to prednisolone doses

cDMARDS conventional disease-modifying anti-rheumatic drugs, DAS28-ESR disease activity score in 28 joints using erythrocyte sedimentation rate, HBsAg hepatitis B surface antigen, HBsAb hepatitis B surface antibody, HBCAb hepatitis B core antibody, HCV hepatitis C virus
until reaching remission was 2.2 times (0.59) and 1.1 years (0.35), respectively.

**Prediction of remission from the five machine learning methods**

In all machine learning methods for predicting remission, the accuracy and AUROC curve values were in the ranges of 52.8–72.9% and 0.512–0.694, respectively (Table 2). The ranges of the accuracy and AUROC curve for remission prediction were 59.8–62.0% and 0.596–0.619 in all bDMARDs, 68.4–70.0% and 0.633–0.655 in TNF inhibitors, and 52.8–58.3% and 0.538–0.607 in non-TNF inhibitors, respectively. Among the bDMARDs, the ranges for accuracy and AUROC curve were 67.4–69.8% and 0.623–0.688 for adalimumab, 64.6–67.7% and 0.619–0.656 for etanercept, 61.1–66.7% and 0.615–0.694 for golimumab, 64.6–72.9% and 0.511–0.626 for infliximab, 63.2–68.4% and 0.598–0.679 for abatacept, and 56.1–61.0% and 0.512–0.556 for tocilizumab, respectively. For each bDMARD, the accuracy and AUROC curve were similar across the different machine learning models.

**Important features for remission in XAI**

The SHAP method for remission was used to determine the influences of the variables that contributed to remission in the prediction model. The interpretations of the feature importance with the Shapley plot are shown in Fig. 3 and Additional file: Table S4, where the features feature importance with the Shapley plot are shown in Fig. 3 and Additional file: Table S4, where the features are listed in order of their absolute values.

In all bDMARDs, the ESR was the most important feature for predicting remission (SHAP value = −0.136), with low and high ESR levels associated with remission and remission failure, respectively. The DAS28-ESR was the second most important feature and had a negative association with remission (−0.091). The hemoglobin was the third most important feature and had a positive association with remission (0.089). In TNF inhibitors, ESR was the most important feature (−0.210), followed by hemoglobin and DAS28-ESR (0.152 and −0.144, respectively). In non-TNF inhibitors, methotrexate dose was the most important feature (0.167), followed by CRP and ESR (0.143 and −0.140, respectively).

Age was the most important feature for adalimumab (−0.250), fourth for golimumab (−0.033), and fifth for tocilizumab (−0.097). RF was the most important feature for etanercept (−0.234), but it was not among the top five features for the other bDMARDs. ESR was the most important feature for infliximab (−0.514) and golimumab (−0.227) and was the most important feature of most bDMARDs. Disease duration was the most important feature for abatacept (−0.804), third for infliximab (−0.297), and sixth for golimumab (−0.024). CRP was the most important feature for tocilizumab (0.135) and fifth important feature for etanercept (0.102); however, CRP was not among the top features for the other bDMARDs.

**Rankings of important features in bDMARDs**

Table 3 shows the order of the average of the SHAP value ranks from the Shapley plot in the bDMARDs. The degree and direction of contribution of the variables to remission were different for each bDMARD. Among the variables, the ESR had the highest average ranking (4.0) and had a negative association with remission for all bDMARDs. Hemoglobin had the second-highest average ranking (5.3) and had a positive association with remission for all bDMARDs except for golimumab (no association). The age and DAS28-ESR factors had the third and fourth highest average rankings (6.67 and 7.83, respectively) and had negative associations with remissions for adalimumab, etanercept, infliximab, golimumab, and tocilizumab. For abatacept, DAS28-ESR was positively associated with remission, and age had a nonlinear relationship with remission.

The relationship between RF levels and remission was different for each bDMARD. RF was positively associated with remission in adalimumab, but negatively associated with remission in etanercept and tocilizumab. RF had a nonlinear relationship with remission in infliximab and abatacept, and no association with remission in golimumab. In terms of ACPA, low ACPA was associated with remission in all bDMARDs (negative association) except tocilizumab (positive association). The elevation of CRP was associated with remission in bDMARDs (positive association) except for adalimumab and golimumab (no association). In most bDMARDs, disease duration, platelet, cholesterol, and triglyceride showed negative associations with remission. ANA had a negative association with remission for infliximab and abatacept.

**Predictive model for remission without increasing prednisolone dose**

We built a machine learning model for remission without increasing prednisolone dose as another outcome (Additional file: Table S5). Among the 1397 follow-ups, 537 were classified as remission without increasing prednisolone dose. The ranges of accuracy and AUROC were 54.1–72.9% and 0.517–0.698, respectively, which were similar to the results for predicting remission. In the Shapley plots, compared with the outcomes for predicting remission, the SHAP scores had slight fluctuations while the order of the variables was similar (Additional file: Figure S1 and Table S6). In the ranking of important features, there was a slight change due to the difference in the SHAP value of each variable (Additional file: Table S7). However, important features such as ESR,
DAS28-ESR, CRP, age, hemoglobin, RF, and ACPA retained high rankings for predicting remission.

**Discussion**

In the prediction models of remission with all machine learning methods, the ranges of accuracy and AUROC were 52.8–72.9% and 0.512–0.694, respectively. Notably, based on the machine learning models for predicting remission, we identified important clinical features that were associated with remission after treatment with bDMARDs. Although it is possible to estimate the importance of each variable by linear regression analysis,

### Table 2 Prediction of remission for bDMARDs

| Follow-up period (year), mean (sd) | Remission/total ( Measurement Baseline Lasso Ridge SVM Random forest Xgboost) |
|-----------------------------------|--------------------------------------------------------------------------------|
| All bDMARDs 0.96 (0.30)          | 564/1397 (40.4%)                                                 | Sensitivity 0.0% 33.1% 29.6% 24.9% 0.6% 32.2% |
|                                   |                                                                      | Specificity 100.0% 79.9% 83.1% 85.1% 100.0% 80.5% |
|                                   |                                                                      | Accuracy 59.6% 61.0% 61.5% 60.5% 59.8% 62.0% |
|                                   |                                                                      | AUROC 0.500 0.614 0.619 0.602 0.608 0.596 |
| TNF inhibitors 0.93 (0.32)        | 252/793 (31.8%)                                                 | Sensitivity 0.0% 10.7% 21.3% 9.3% 0.0% 20.0% |
|                                   |                                                                      | Specificity 100.0% 97.5% 92.6% 96.0% 100.0% 91.4% |
|                                   |                                                                      | Accuracy 68.2% 69.6% 70.0% 68.4% 68.4% 68.9% |
|                                   |                                                                      | AUROC 0.500 0.649 0.655 0.633 0.644 0.637 |
| Non-TNF inhibitors 1.01 (0.27)    | 312/604 (51.7%)                                                 | Sensitivity 0.0% 62.4% 64.5% 62.4% 57.3% 52.8% |
|                                   |                                                                      | Specificity 100.0% 52.3% 51.7% 51.7% 33.3% 49.8% |
|                                   |                                                                      | Accuracy 51.7% 57.8% 57.8% 58.3% 55.3% 52.8% |
|                                   |                                                                      | AUROC 0.500 0.605 0.607 0.606 0.586 0.538 |
| Adalimumab 0.93 (0.31)            | 91/289 (31.5%)                                                 | Sensitivity 0.0% 22.2% 29.6% 37.0% 0.0% 14.8% |
|                                   |                                                                      | Specificity 100.0% 91.5% 88.1% 81.4% 100.0% 93.2% |
|                                   |                                                                      | Accuracy 68.5% 69.8% 69.8% 67.4% 68.6% 69.8% |
|                                   |                                                                      | AUROC 0.500 0.680 0.688 0.663 0.623 0.629 |
| Etanercept 0.99 (0.34)            | 75/220 (34.1%)                                                 | Sensitivity 0.0% 29.5% 36.4% 40.9% 0.0% 22.7% |
|                                   |                                                                      | Specificity 100.0% 86.0% 83.7% 79.1% 100.0% 88.4% |
|                                   |                                                                      | Accuracy 65.9% 67.7% 67.7% 66.2% 66.2% 64.6% |
|                                   |                                                                      | AUROC 0.500 0.634 0.656 0.643 0.656 0.619 |
| Golimumab 0.97 (0.30)             | 41/122 (33.6%)                                                 | Sensitivity 0.0% 0.0% 41.7% 50.0% 0.0% 16.7% |
|                                   |                                                                      | Specificity 100.0% 100.0% 79.2% 66.7% 100.0% 95.8% |
|                                   |                                                                      | Accuracy 66.4% 66.7% 63.9% 61.1% 66.7% 66.7% |
|                                   |                                                                      | AUROC 0.500 0.615 0.694 0.623 0.659 0.635 |
| Infliximab 0.85 (0.32)             | 45/162 (27.8%)                                                 | Sensitivity 0.0% 30.8% 23.1% 30.8% 0.0% 15.4% |
|                                   |                                                                      | Specificity 100.0% 82.9% 88.6% 80.0% 100.0% 85.7% |
|                                   |                                                                      | Accuracy 72.2% 66.7% 70.8% 64.6% 72.9% 66.7% |
|                                   |                                                                      | AUROC 0.500 0.595 0.626 0.544 0.600 0.511 |
| Abatacept 0.99 (0.30)              | 62/194 (32.0%)                                                 | Sensitivity 0.0% 11.1% 30.6% 38.9% 0.0% 27.8% |
|                                   |                                                                      | Specificity 100.0% 94.9% 84.6% 75.6% 100.0% 82.1% |
|                                   |                                                                      | Accuracy 68.0% 68.4% 68.4% 63.2% 68.4% 64.9% |
|                                   |                                                                      | AUROC 0.500 0.635 0.679 0.636 0.618 0.598 |
| Tocilizumab 1.01 (0.26)            | 250/410 (61.0%)                                                 | Sensitivity 0.0% 76.0% 81.3% 80.0% 80.0% 77.3% |
|                                   |                                                                      | Specificity 100.0% 29.2% 22.9% 22.9% 21.9% 22.9% |
|                                   |                                                                      | Accuracy 61.0% 57.7% 58.5% 61.0% 56.9% 56.1% |
|                                   |                                                                      | AUROC 0.500 0.552 0.555 0.556 0.522 0.512 |

bDMARDs: adalimumab, etanercept, golimumab, infliximab, abatacept, and tocilizumab. TNF inhibitors: adalimumab, etanercept, golimumab, infliximab. non-TNF inhibitors: abatacept and tocilizumab. N: total number of samples for the drug category. Baseline accuracy: remission rate not achieved by clinicians except for tocilizumab and non-TNF inhibitors; baseline AUROC: the value when selecting random or one side.
Fig. 3 Shapley plots for bDMARDs. Shapley plots show the SHAP values in the order of the important variables that contribute to remission. The feature values change from light (low) to dark (high) for each variable. For age, for example, the lighter colors represent lower age, whereas the darker colors represent higher age. For adalimumab, increasing (positive) SHAP values with lighter colors indicate that lower ages are strongly related to remission, whereas decreasing (negative) SHAP values with darker colors indicate that higher ages are strongly related to remission failure. Therefore, linear changes in the feature values are expressed in color, and the SHAP values (impact on model output) indicate closer to remission or remission failure based on the feature values. DAS, disease activity score; ESR, erythrocyte sedimentation rate; LTBI, latent tuberculosis infection; IGRA, interferon-gamma release assay; HBcAb, hepatitis B core antibody; CMIND, psychiatric comorbidity; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; CDIABET, diabetes mellitus and its complications; BMI, body mass index.
we determined that machine learning would complement statistical methods due to the complex relationships between the variables and remission. Some significant clinical features for remission prediction were commonly identified in the bDMARDs, albeit with slight differences in the impact between the bDMARDs.

Guan et al. used machine learning to predict the responses to TNF inhibitors in patients with RA using clinical and genetic markers [10]; the authors created a Gaussian process regression model to predict the changes in DAS28 and classified the patients into responders and non-responders. However, Guan et al. used variables that are difficult to obtain in routine practice such as genetic variables, and their outcomes were different from our study. Norgeot et al. used a longitudinal deep learning model to predict controlled (remission or low activity) or uncontrolled state (moderate or high activity) with clinical disease activity index in the next clinical visit [11]; their study showed good performance, but it was not aimed at predicting the therapeutic response of the biologics, but rather predicting the clinical disease activity index at the next visit. Because the goal of our study was to predict the response of biologics, it is difficult to compare our prediction of remission with their outcome.

As opposed to how machine learning models, such as those using deep learning are “black-box” models to explain the reason for prediction, the XAI machine learning method provides reasons for prediction in a manner that lay users can easily understand. For interpretability, the SHAP method, which is based on the Shapley values, was recently presented [18]. The Shapley value employs a method based on game theory, which was introduced to suggest how to fairly distribute payout among the features [19]. This theory has influenced various fields and has recently been used in machine learning to improve the interpretability of complex models. The SHAP method is a unified framework that improves interpretability while maintaining predictability of complex models with machine learning. Using the SHAP method, we identified the characteristics of the important variables that contribute to prediction of remission in a complex cohort dataset. In the use of healthcare data, it is important to discern the relationships between the variables in clinical, genomic, and other types of healthcare data. This proposed method is expected to provide insights for finding the relationships among numerous variables in the integration of large-scale healthcare data.

Among various baseline variables, several laboratory findings were identified as important features that ranked highly for predicting remission. For all the bDMARDs, the most important feature was the ESR, which is a variable predictive of disease activity [20, 21]. Hemoglobin was the second most important feature in our study; considering how anemia is associated with disease activity [22] and erosion progression [23], hemoglobin may be an important factor indicating disease states in patients with RA. The RF and ACPA were also important for prediction of remission and contributed to determination of the direction of treatment in

| Table 3 Rankings of the important features for the prediction of remission in each biologic |
|-----------------------------------------------|------------|----------|----------|----------|----------|----------|----------|----------|
| Clinical feature                             | Average ranking | Adalimumab | Etanercept | Infliximab | Golimumab | Abatacept | Tocilizumab |
| ESR                                           | 4.0        | -0.041   | -0.155   | -0.514   | -0.227   | -0.356   | -0.104   |
| Hemoglobin                                    | 5.3        | +0.134   | +0.071   | +0.401   | 0        | +0.656   | +0.061   |
| Age                                           | 6.7        | -0.250   | -0.040   | -0.230   | -0.033   | 0.241    | -0.097   |
| DAS28-ESR                                     | 7.8        | -0.059   | -0.125   | -0.116   | -0.065   | +0.114   | -0.100   |
| Rheumatoid factor                             | 8.0        | +0.029   | -0.234   | 0.0176   | 0        | 0.273a   | -0.075   |
| Anti-CCP antibody                              | 8.3        | -0.052   | -0.029   | -0.285   | -0.070   | -0.347   | +0.029   |
| CRP                                           | 8.7        | 0        | +0.102   | +0.117   | 0        | +0.350   | +0.135   |
| Disease duration                              | 11.5       | -0.081   | 0        | 0.297a   | -0.024   | -0.804   | 0        |
| Methotrexate dose                             | 11.7       | 0        | 0        | 0.046a   | 0        | +0.668   | +0.049   |
| Platelet                                      | 11.8       | 0        | -0.132   | 0        | -0.026   | -0.448   | -0.074   |
| Cholesterol                                   | 12.5       | -0.052   | -0.042   | -0.254   | 0        | 0        | -0.080   |
| ALT                                           | 15.0       | -0.081   | 0        | +0.245   | 0        | 0        | -0.079   |
| BUN                                           | 15.0       | 0        | +0.032   | 0        | 0        | -0.403   | +0.134   |
| Triglyceride                                  | 16.0       | -0.036   | -0.023   | 0        | 0        | 0        | -0.067   |
| ANA                                           | 16.0       | 0        | 0        | -0.060   | 0        | -0.430   | 0        |

*A nonlinear relationship such as quadratic effect or mixed effect between drugs and variables. The average ranking was obtained by averaging the rankings of the 6 bDMARDs.

ESR erythrocyte sedimentation rate, DAS28-ESR disease activity scores in 28 joints using the erythrocyte sedimentation rate, CRP C-reactive protein, ALT alanine aminotransferase, BUN blood urea nitrogen, ANA anti-nuclear antibody
patients with RA [24, 25]. However, several studies have shown conflicting results on the relationship between RF and ACPA in response to TNF inhibitors [26, 27]. In our study, the RF and ACPA were associated with remission in various degrees of impact and direction for each bDMARD. Moreover, RF was not linearly related to remission for infliximab and abatacept; as such, changes in the feature value were not significantly related to either remission or remission failure.

This study has some obvious limitations. First, the dosage intervals and doses of biologics were not considered. Second, this study did not distinguish between the primary response failure (i.e., failure of clinical improvement) and secondary response failure (i.e., loss of response after clinical improvement) [27]. Third, this study did not provide evidence as to how the important features of each bDMARD were related to their mechanisms of action. Fourth, because this study focused on the important features of the variables needed for prediction in the machine learning model, the performance of machine learning was not confirmed using external test sets from other RA cohort data. Fifth, because this study included patients treated with first bDMARDs and excluded those who had been previously treated with bDMARDs, such patient characteristics should be considered in the interpretation of the Shapley plot. Sixth, the prediction of response to biologics is difficult because it can be affected by individual variances. In addition, it is difficult to enhance the predictive power because there is a limit in the amount of variables that can be obtained in routine clinical practice. Importantly, the problem of missing values in real-world data is one of the limitations of this study. Lastly, although the KOBIO registry is an inception cohort of consecutive patients treated with biologics, those who failed to meet the inclusion criteria or did not consent to participate in the registry were not included, which may lead to a selection bias.

Conclusion
We successfully developed machine learning models to predict remission as a response to different bDMARDs in active RA patients based on their clinical profiles. Using these models, the XAI was able to identify important clinical features associated with remission according to the biologics used. We noted that some important features were more strongly associated with remission, albeit the order of their relative importance was different for each biologic. Our results suggest that an advanced machine learning approach may be helpful for supporting clinical decisions to improve treatment outcomes with biologics in RA patients.

Additional contributions The registry was funded by the Korean College of Rheumatology, which had no involvement in the study design, collection, analysis, and interpretation of the data; in writing the manuscript; or in the decision to submit the manuscript for publication. We would like to thank all members of The Korean College of Rheumatology Biology (KOBIO) registry. We thank Dr. Joon Seo Lim from the Scientific Publications Team at Asan Medical Center for his editorial assistance with preparing this manuscript.

Abbreviations
ACPA: Anti-cyclic citrullinated peptide antibody; ANA: Anti-nuclear antibody; AUROC: Area under the receiver operating characteristics; bDMARDs: Biologic disease-modifying anti-rheumatic drugs; cDMARDs: Conventional disease-modifying anti-rheumatic drugs; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; DAS28-ESR: Disease activity scores in 28 joints using the erythrocyte sedimentation rate; KOBIO: Korean College of Rheumatology Biologies and Targeted Therapy Registry; RA: Rheumatoid arthritis; RF: Rheumatoid factor; TNF: Tumor necrosis factor; SHAP: Shapley additive explanations; SD: Standard deviation; tsDMARDs: Targeted synthetic disease-modifying anti-rheumatic drugs; XAI: Explainable artificial intelligence

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13075-021-02567-y.

Additional file 1: Table S1. Hyperparameters for bDMARDs. Table S2. Hyperparameters for prediction of remission without increasing prednisolone dose. Table S3. Proportions of missing data in each variable. Table S4. SHAP values for the variables in Shapely plots. Table S5. Prediction of remission without increasing prednisolone dose for bDMARD. Table S6. SHAP values for variables in Shapely plots. Table S7. Order of important features for prediction of remission without increasing prednisolone dose in each bDMARD. Figure S1. Shapley plots predicted.

Authors’ contributions
JSO had full access to all of the data used in the study and takes responsibility for the integrity of the data, study supervision, and accuracy of its analysis. BSK, SE, and JSO contributed to the study conception and design. All authors performed the acquisition, analysis, and interpretation of data. BSK, SE, and JSO wrote the manuscript. BSK, SE, and JSO were involved in the statistical modelling. JSO obtained funding. KS, HY, CH, and DHK contributed to the administrative, technical, or material support. YGK, CKL, BY, and JSO contributed to the supervision. All authors took part in revising the manuscript critically for important intellectual content, and gave their final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Funding
This study was supported by a grant (2020IP0025) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, and a grant (20004927) supported by the Technology Innovation Program funded by the Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea.

Availability of data and materials
Data are available from the Clinical Research Committee of KOBIO under the Korean College of Rheumatology for researchers who meet the criteria for access to confidential data. To request data, please contact Kichul Shin, MD, PhD, Director of the Korean College of Rheumatology Biologies Registry, Associate Professor of the Division of Rheumatology, Director of Logistics Planning at SMG-SNU, Boramae Medical Center, 20 Boramae-ro-5-gil, Dongjak-gu, Seoul, 07061, Korea; Tel: 822 870 3204; Fax: 822 870 3866; Email: rk.ca.uns@1bedik.
Declarations

Ethics approval and consent to participate
The patients provided informed consent prior to registration. Ethical approvals for the KOBIO-RA were obtained from the institutional review boards of all 38 participating institutions, including the Institutional Review Board of Inje University Seoul Paik Hospital (PAIK 2018-11-005).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea. 2. Department of Management Engineering, College of Business, KAIST, Seoul, Korea. 3. Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Big Data Research Center, Asan Institute of Life Sciences, Asan Medical Center, Seoul, Korea. 5. Division of Rheumatology, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Korea. 6. Department of Information Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, Korea. 7. Department of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

References
1. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kershbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99. https://doi.org/10.1136/annrheumdis-2019-216655.
2. Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357–75. https://doi.org/10.1111/1756-185X.13513.
3. Singh JA, Saag KG, Bridges SL Jr, Alarcon GS, Annauci RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26. https://doi.org/10.1002/art.39480.
4. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Tech LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400–11. https://doi.org/10.1002/art.20217.
5. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–9. https://doi.org/10.1056/NEJM19990108.00.001.
6. Kiehl W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The medication and medication costs of three anti-tumor necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67(9):1229–34. https://doi.org/10.1136/ard.2007.083675.
7. Park YJ, Chung MK, Hwang D, Kim WJ. Proteomics in rheumatoid arthritis research. Immune Netw. 2015;15(4):177–85. https://doi.org/10.4110/in.2015.5.4.177.
8. Plant D, Barton A. Adding value to real-world data: the role of biomarkers. Rheumatology (Oxford). 2020;59(5):131–8. https://doi.org/10.1093/rheuma/tke113.
9. Sutcliffe M, Radley G, Barton A. Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors? Expert Rev Clin Immunol. 2020;16(4):389–96. https://doi.org/10.1080/1744666X.2020.1740594.
10. Guan Y, Zhang H, Quang D, Wang Z, Parker SCJ, Pappas DA, et al. Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers. Arthritis Rheumatol. 2019;71(12):1987–96. https://doi.org/10.1002/art.41056.
11. Norgeot B, Gilsberg BS, Trupin L, Litvieu D, Gianfrancesco M, Oskotby B, et al. Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis. JAMA Netw Open. 2019;2(5):e190366. https://doi.org/10.1001/jamanetworkopen.2019.0666.
12. Lundberg SM, Erion GG, Lee S-L. Consistent individualized feature attribution for tree ensembles. In: arXiv e-prints. 2018: arXiv:1802.03888.
13. Shin K, Choi S, Kwak S-K, Park Y-B, Sung Y-K, Choi C-B, et al. AB1066 Korean Biologics Registry of Patients with Systemic Rheumatic Disease (KOBIJO): a nationwide registry to assess adverse events associated with biologic treatment in Korea. Ann Rheum Dis. 2014;73(Suppl):ii153–4.
14. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc B (Methodological). 1996;58(1):267–88. https://doi.org/10.1111/1756-1611.1996.tb00208.x.
15. Suykens JA, Vandewalle J. Least squares support vector machine classifiers. Neural Process Lett. 1999;9(3):293–300. https://doi.org/10.1023/A:1018736438099.
16. Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(2):18–22. http://cran.r-project.org/doc/Rnews/Rnews_2002-2.pdf.
17. Chen T, Guerini H. XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. San Francisco: Association for Computing Machinery; 2016. p. 785–94.
18. Lundberg SM, Lee S-L. A unified approach to interpreting model predictions. In: Guyon I, et al, editors. Advances in Neural Information Processing Systems. Long Beach: NIPS; 2017. p. 4765–7477. http://papers.nips.cc/paper/7062-a-unified-approach-to-interpreting-modelpredictions.pdf.
19. Arrow KJ, Baranik E, Blackwell D, Bott R, Daley N, Dresher M, Gale D, Gillies DR, Glibkies I, Gross O, et al: Contributions to the theory of games (AM-28), Volume II: Princeton University Press; 1953.
20. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389–95. https://doi.org/10.1136/annrheumdis-2013-204016.
21. Vastesaeger N, Kutzbach AG, Armital H, Pavella K, Lazar MA, Moots RJ, et al. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatol (Oxford). 2016;55(8):1466–76. https://doi.org/10.1093/rheumatology/kew179.
22. Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Ann J Med. 2004;116(Suppl 7A):S50–75.
23. Moller B, Scheer A, Forger F, Villiger PM, Finckh A. Swiss Clinical Quality Management Program for Rheumatic D: Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis. 2014;73(4):691–6. https://doi.org/10.1136/annrheumdis-2012-202709.
24. Canhao H, Rodrigues AM, Mourao AF, Martins F, Santos MJ, Canas-Silva J, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012;51(11):2020–6. https://doi.org/10.1093/rheumatology/kes184.
25. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69–74. https://doi.org/10.1136/annrheumdis-2007-084715.
26. Cuppen BV, Welting PM, Sprenger JJ, Bijlsma JW, Mariniussen AC, van Laar JM, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2016;55(9):826–39. https://doi.org/10.1093/rheumatology/kew421.
27. Tak PP. A personalized medicine approach to biological treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford). 2012;51(4):600–9. https://doi.org/10.1093/rheumatology/ker300.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.